Emkay Global Financial' research report on Infosys
Infosys delivered an in-line operating performance in Q2. Revenue grew 2.2% CC QoQ, aided by ~20bps contribution from M&As and improved realizations from Project Maximus amid soft volumes. EBITM expanded by 20bps QoQ to 21.0%, coming in slightly lower than our estimate. Large deal TCV in Q2 was strong at USD3.1bn, of which 67% is net new. In addition, Infosys signed a USD1.6bn mega-deal with NHS (100% net new) after the end of Q2; the deal will start ramping up within the current fiscal year. The company has narrowed its FY26 revenue growth guidance to 2-3% CC (earlier 1-3%), implying CQGR of -0.2% to -1.5% in H2. H2 is expected to be seasonally softer due to fewer working days, furloughs, and calendar effects, and the revised guidance incorporates elevated uncertainty at the lower end and a stable environment at the upper end. The guidance does not include any revenue from the Telstra JV (expected to close in H2; Versent reported FY25 revenue of AUD211.4mn). It has retained EBITM guidance range of 20-22% for FY26. We largely retain FY26-28E EPS, factoring in an in-line Q2.
Outlook
We retain BUY on the stock with TP of Rs1,650 at 21x Sep-27E EPS.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.